Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.70 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.70 |
| ▸ | SSTR2 | P30874 | 8/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 7/20 | 0.44 |
| ▸ | SSTR5 | P35346 | 7/20 | 0.44 |
| ▸ | TERF2 | Q15554 | 2/20 | 0.43 |
| ▸ | KLK7 | P49862 | 2/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 3/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21610478 | 0.95 | KDM1A (0.70) | KDM1ARCOR1SSTR2SSTR4SSTR5 | |
| SCHEMBL25455642 | 0.94 | KDM1A (0.77) | KDM1ARCOR1SSTR2SSTR4SSTR5 | |
| SCHEMBL25455822 | 0.94 | KDM1A (0.77) | KDM1ARCOR1SSTR2SSTR4SSTR5 | |
| SCHEMBL25466596 | 0.94 | KDM1A (0.77) | KDM1ARCOR1SSTR2SSTR4SSTR5 | |
| SCHEMBL20366251 | 0.94 | KDM1A (0.77) | KDM1ARCOR1SSTR2SSTR4SSTR5 | |
| SCHEMBL22106116 | 0.93 | KDM1A (0.72) | KDM1ARCOR1SSTR2SSTR4SSTR5 | |
| SCHEMBL21788824 | 0.93 | KDM1A (0.72) | KDM1ARCOR1SSTR2SSTR4SSTR5 | |
| SCHEMBL19546033 | 0.93 | KDM1A (0.72) | KDM1ARCOR1SSTR2SSTR4SSTR5 | |
| SCHEMBL21504325 | 0.91 | KDM1A (0.65) | KDM1ARCOR1SSTR2SSTR4SSTR5 | |
| SCHEMBL22677561 | 0.91 | KDM1A (0.68) | KDM1ARCOR1SSTR2SSTR4SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200069767-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069767-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | MAVS, MYD88, CD47 | KDM1A 4216/4885RCOR1 3890/4885SSTR2 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.